At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Nov 2, 2026 at 07:30 ET
Cytokinetics announced upcoming presentations of aficamten data at the HCM Medical Society Scientific Sessions, including two late-breaking oral abstracts from the ACACIA-HCM CMR study and a FOREST-HCM analysis. The company also reiterated its plan to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026, following positive Phase 3 topline results.
- Cytokinetics will present two late-breaking oral abstracts and one poster on aficamten at the HCM Medical Society Scientific Sessions on November 6, 2026.
- The ACACIA-HCM CMR study evaluates aficamten's effect on cardiac structure and function in nonobstructive hypertrophic cardiomyopathy.
- The FOREST-HCM analysis examines left ventricular systolic dysfunction in long-term aficamten therapy for obstructive HCM.
- Cytokinetics plans to submit a Supplemental New Drug Application for aficamten in nonobstructive HCM in Q4 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access